Skip to main content

Grifols Value Stock - Dividend - Research Selection

Grifols SA

ISIN: ES0171996087, WKN: A2ABUQ

Market price date: 08.01.2021
Market price: 15,86 EUR




Grifols SA Fundamental data and company key figures of the share

Annual reports in EUR
Key figures 21-03-2020
Cash flow
Net operating cash flow 573.000.000
Capital Expenditures -310.000.000
Free cash flow 263.000.000
Balance sheet
Total Equity 6.846.000.000
Liabilities & Shareholders equity 15.543.000.000
Income statement
Net income 625.000.000
Eps (diluted) 0,910
Diluted shares outstanding 686.813.000
Net sales/revenue 5.099.000.000

Fundamental ratios calculated on: 08-01-2021

Ratios
Key figures 08-01-2021
Cash flow
P/C 0,00
   
P/FC 0,00
Balance sheet
ROI4,02
ROE44,05
Income statement
P/E17,43
Div. Yield0,00%
P/B0,00
P/S2,14


Do you want to do make a detailed fundamental analysis of this stock?

✓ NEW Fundamental API Access to 500 data points per month
Fundamental data up to 25 years
Comparison to all other stocks by the FScore
Time saving!

How our site works ...

Non-binding 7 days without automatic subscription
 No termination required after the free week
Finanzoo fundamental analysis
Data updated daily
Virtual depots
Share alarms via email
Subscription can be canceled at any time at the end of the month 
Choice of desired shares
Over 2000 stock analyzes available
Bitcoin payment possible if you do not want to subscribe

Price for monthly subscription $ 19.99 / month including VAT.



DescriptionData
SymbolGRF-P.MC
Market Capitalization13.211.466.752,00 USD
CountrySpain
IndicesIBEX 35
SectorsHealth service
Raw Data SourceIFRS in Millionen EUR
Stock Split2016-01-05,2.0000/1.0000; 2016-01-04,2.0000/1.0000; 2012-12-11,2.0000/1.0000
Internetwww.grifols.com


Description of the company

We were founded in 1940 in Barcelona, Spain by Dr. José Antonio Grifols i Roig, a specialist and pioneer in blood transfusions and clinical analysis and the grandfather of our current Chairman of the Board. We have been making and selling plasma derivative products for more than 70 years. Over the last 25 years, we have grown from a predominantly domestic Spanish company into a global company by expanding both organically and through acquisitions throughout Europe, the United States, Latin America and Asia.

 

We were incorporated in Spain as a limited liability company on June 22, 1987 under the name Grupo Grifols, S.A., and we changed our name to Grifols, S.A. in 2005. We conduct business under the commercial name “Grifols.” Our principal executive office is located at Avinguda de la Generalitat, 152 Parque Empresarial Can Sant Joan, 08174 Sant Cugat del Vallès, Barcelona, Spain and our telephone number is +34 93 571 0500. Our registered office is located at c/Jesús y María, 6, Barcelona, Spain.

 

We are a vertically integrated global producer of plasma derivatives. Our activities include sourcing raw material, manufacturing various plasma derivative products and selling and distributing final products to healthcare providers. As of December 31, 2016 we had 171 operating plasma collection centers located across the United States. We have expanded our plasma collection network through a combination of organic growth and acquisitions and the opening of new plasma collection centers, and we plan to reach 225 FDA-approved plasma collection centers by 2021. We also produce diagnostic and hospital products.

 

Our Class A shares have been listed on the Spanish Stock Exchanges since we completed our initial public offering on May 17, 2006 and are quoted on the SIBE under the ticker symbol “GRF.” In January 2008, we became part of the IBEX-35 Index, which comprises the top 35 listed Spanish companies by liquidity and market capitalization. Our Class B shares were issued as part of the consideration for the Talecris acquisition and are listed on the Spanish Stock Exchanges and quoted on the SIBE under the ticker symbol “GRF.P.” Our Class B shares are also traded in the United States on the NASDAQ Global Select Market in the form of ADSs, evidenced by ADRs, under the symbol “GRFS.” Each ADS represents one of our Class B shares. Our ADSs are currently traded in U.S. dollars. In November 2011, our ADSs were added to the NASDAQ Biotechnology Index.

The Finanzoo GmbH assumes no liability for the accuracy of the information! All information is provided without warranty. Sources:: www.bundesanzeiger.de, www.sec.gov, www.grifols.com